Trial Profile
A Phase I, Double Blind, Placebo-controlled, Randomized 4-way Alternating Cross-over Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Single Ascending Doses of ASP3652 in Healthy Young Caucasian Male and Female Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Jul 2020
Price :
$35
*
At a glance
- Drugs ASP 3652 (Primary)
- Indications Interstitial cystitis
- Focus Adverse reactions
- Sponsors Astellas Pharma Europe Ltd
- 26 Jul 2020 Results published in the Advances in Therapy
- 22 Apr 2014 New trial record